Dorsey & Whitney Trust CO LLC Has $673,000 Position in Gilead Sciences, Inc. (GILD)

Dorsey & Whitney Trust CO LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,505 shares of the biopharmaceutical company’s stock after purchasing an additional 2,096 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Gilead Sciences were worth $673,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Pioneer Investment Management Inc. grew its position in shares of Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock valued at $247,245,000 after acquiring an additional 1,595,085 shares during the period. Neuberger Berman Group LLC grew its position in shares of Gilead Sciences by 90.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock valued at $182,839,000 after acquiring an additional 1,229,916 shares during the period. Harbour Capital Advisors LLC grew its position in shares of Gilead Sciences by 6,595.9% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock valued at $17,262,000 after acquiring an additional 1,203,557 shares during the period. Principal Financial Group Inc. grew its position in shares of Gilead Sciences by 41.2% in the 2nd quarter. Principal Financial Group Inc. now owns 3,909,105 shares of the biopharmaceutical company’s stock valued at $276,687,000 after acquiring an additional 1,140,112 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after acquiring an additional 1,092,206 shares during the period. 76.30% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/11/22/dorsey-whitney-trust-co-llc-has-673000-position-in-gilead-sciences-inc-gild.html.

A number of research analysts have recently commented on the stock. Leerink Swann lifted their price objective on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research report on Thursday, October 19th. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Cowen and Company restated an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Berenberg Bank restated a “buy” rating and set a $86.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $84.87.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the completion of the transaction, the insider now owns 2,996,766 shares in the company, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. Insiders have sold a total of 666,819 shares of company stock worth $52,303,086 over the last three months. Insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.51 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The firm has a market cap of $94,221.18, a P/E ratio of 7.53, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period in the previous year, the firm posted $2.75 EPS. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply